NCT04670211 (SARPE) is a clinical trial of maxillary distractor in Malocclusion, sponsored by ZOL.

Who is sponsoring NCT04670211?

NCT04670211 is sponsored by ZOL.

What drugs are being tested in NCT04670211?

Interventions in NCT04670211: maxillary distractor.

What condition does NCT04670211 study?

NCT04670211 studies Malocclusion.

Is NCT04670211 still recruiting?

NCT04670211 is currently status unknown. Last updated 20 April 2021.

Last reviewed 2021-04-20 · How we verify

NCT04670211: SARPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Comparison of Tooth-borne, Bone-borne and Hybrid Distraction Following SARPE.

Status unknown Last updated 20 April 2021

What this trial tests

trial testing maxillary distractor in Malocclusion in 90 participants. Status unknown.

Timeline

1 May 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	ZOL
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	90
Start date	1 May 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023

Drugs / interventions tested

maxillary distractor

Conditions studied

Malocclusion — all drugs for Malocclusion →

Sponsor

ZOL — full company profile →

Who can join

12 and older, any sex, with Malocclusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will perform a prospective, non-randomized observational study. The aim of this study is to evaluate stability of tooth-borne, bone-borne and hybrid expansion following SARPE by using data collected according to the existing SARPE follow-up protocol. The insights of this study might elucidate the preferred expansion technique and improve surgical technique.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Malocclusion

Currently open trials in the same condition.

NCT05684510 — Treatment of Mild Class II Malocclusion in Adult Patients With Clear Aligners Versus Fixed Multibracket Therapy · NA · recruiting
NCT07290790 — A Prospective Multicenter Clinical Investigation Evaluating the Accuracy of the Trimline Design When Treated With SureSm · NA · recruiting
NCT06858670 — Effectiveness of Auxiliary Segmental Lingual Appliances in Leveling the Curve of Wilson at Second Molars · NA · recruiting
NCT06536335 — Evaluation of the Perceived Experience of Patients Treated With Aligners With Two Different Timings · NA · recruiting
NCT07094581 — Evaluation of the Effect of Adenoid Hypertrophy on the Masseter Muscle in Children: A Comparative Ultrasonographic Study · recruiting

Other ZOL trials

Trials by the same sponsor.

NCT02970253 — Direct Anterior Approach (DAA) for Total Hip Arthroplasty (THA): Capsular Resection Versus Capsular Flap Retention · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04670211 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ZOL
Last refreshed: 20 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04670211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing